There’s no doubt about it, urinary tract infections are the worst. It’s burning and itchy, and just when you think it’s gone, it comes back again. But there’s finally a new line of defense for those dealing with these relentless infections.
New types of antibiotics are now available for some of the most troublesome infections. This month, the Food and Drug Administration approved Iterum Therapeutics’ Orlynvah is used for certain types of urinary tract infections that don’t respond well to other drugs.
urinary tract infection These are some of the most common infections encountered by people, especially women. It is estimated that approximately 60% of women in the United States will experience at least one uncomplicated urinary tract infection (urinary tract infection with no signs of structural damage or other health conditions) in their lifetime. In the past, urinary tract infections were easily treated with antibiotics, but today many infections are treatable. resistant At least one or more frontline drugs used against them. This additional durability not only makes it difficult to treat UTIs early before they cause more serious problems, but also increases the risk of recurrent UTIs. Scientists are therefore racing to discover new antibiotics that can treat these resistant infections.
Aurimba is the first drug of its kind. This includes a combination of sulopenem ezadroxil, which belongs to a subclass of antibiotics called penems, and probenecid, a renal tubular transport inhibitor that has been used in the past to prolong the duration of antibiotics in the body. I am. Penem is synthetic antibiotics Although this holds great promise for the treatment of a variety of resistant bacteria, Aurimba is the first oral penem approved in the United States.
This drug is approved to treat certain uncomplicated urinary tract infections caused by the following causes: E. coli, Klebsiella pneumoniae, or Proteus Mirabilis Bacteria. Importantly, Orlynvah recommends treating UTIs with limited oral antibiotic alternative options, such as infections that have not responded to previous treatment or where testing has shown apparent resistance to other drugs. It’s aimed at people who don’t have a choice. The FDA approved Aurinva based on two Phase III trials that found it to be more effective than or equal to other standard antibiotics for uncomplicated urinary tract infections, including resistant infections.
“The FDA’s approval of sulopenem is great news for those of us who have been hoping for a new option to properly treat patients at high risk of suffering from urinary tract infections,” said Infectious Disease Specialist at Yale University’s St. Raphael Campus. Marjorie Golden said. Haven Hospital, which was involved in clinical research on this drug, statement From Itelm. “Based on the totality of clinical data generated, sulopenem has the potential to become an important treatment for use in the community.”
Although Aurimba is valuable to doctors and patients, the drug is not a panacea for urinary tract infections in general. The drug failed clinical trials testing its effectiveness against complicated urinary tract infections and complicated intra-abdominal infections. And, like many new antibiotics, its use will be carefully controlled to slow the emergence of bacterial strains that evolve resistance to it.
Still, Orlynvah can help prevent many of the miseries associated with urinary tract infections. These infections are not always obvious, but can cause pelvic pain, frequent and/or burning urination, and even blood in the urine. If a urinary tract infection is left untreated, it can increase the risk of more serious kidney infections, urethral strictures in men, and even sepsis (a life-threatening inflammation that can cause widespread organ damage) There is.
